Keywords: Novartis, Signifor, Pasireotide, Cushing's disease, Glivec, GIST, EMA, CHMP

EMA panel backs Novartis Cushing’s disease drug; Glivec label change

Article | 23 January 2012

Print This

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Swiss drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in